CLEVELAND, Aug. 3, 2017 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today highlights from the 2017 Annual
Meeting of the American Association of Physicists in Medicine
(AAPM), the largest association of medical physicists in the world,
including presentation of early clinical experience with MRIdian
Linac, the world's only FDA-cleared MRI-guided radiation therapy
system with linear accelerator-based delivery.
The company's MRIdian® System was the focus of 30 abstracts
selected by AAPM including several talks describing the significant
advantages of daily on-table adaptive radiation therapy and its
positive clinical impact on treatment. MR-guided on-table adaptive
therapy, which is currently possible only with the MRIdian System,
allows for dose escalation for SBRT treatments and dose
de-escalation in cases where the critical structures are too close
to the tumor.
The AAPM Scientific Session talks also highlighted MRIdian's
fully integrated workflow for adaptive therapy, which incorporates
complete Monte Carlo dose
replanning to account for changes in the shape and position of the
tumor and adjacent organs in less than two minutes. More than
2,000 on-table adaptive fractions have been delivered using the
MRIdian System, attesting to its growing adoption and clinical
value.
ViewRay featured a number of presentations in the company's
booth given by MRIdian users from five top cancer centers: Henry
Ford Health System in Metro Detroit; University of California, Los Angeles; Washington University in St. Louis; University of
Wisconsin; and University of
Miami. Below are highlights from these talks:
- Carri Glide-Hurst, Ph.D., from Henry
Ford presented on their initial patient experience with
MRIdian Linac including treatment times of 6.25 minutes for 8Gy
stereotactic body radiation therapy (SBRT) treatments and 5 minutes
for prostate intensity modulated radiation therapy (IMRT)
treatments. She also showed MRIdian movies on how the system's
real-time imaging during treatment automatically detected and
paused the treatment when a transient gas bubble shifted the
prostate. Additional patients in the queue for Henry Ford include liver SBRT, retroperitoneal
SBRT and accelerated partial breast irradiation (APBI).
"MRIdian really does take the blindfold off in showing us things
we've never seen before," said Dr. Glide-Hurst. "We're now able to
treat indications that we hadn't really treated previously like
APBI. We're excited about the potential of reducing margins and
getting a conformal delivery with MRI guidance."
- Anthony Doemer, M.S., from
Henry Ford highlighted the
ultra-sharp beam characteristics for the RayZR Double focused MLC.
Because of its innovative design, it removes the need for tongue
and grooves, nearly eliminating any leakage through the leaves
(average leakage, less than 0.001 percent).
"We were able to successfully commission the MLC with great
agreement between measured small beam profiles of 0.2 x 0.4 cm and
larger profiles matching very well with the Monte Carlo simulations with tight conformance
to the beam model," said Mr. Doemer.
- Yingli Yang, Ph.D., from
UCLA presented on MRIdian's high
quality MRI images, specifically the superior soft-tissue image
quality enabled by MRIdian's innovative processing techniques.
Dr. Yang also highlighted early research imaging results
acquired using a new MR acquisition technique reducing the
imaging times of 17 seconds down to approximately 12 seconds. This
3D MRI sequence provides motion artifact-free images with a large
field of view (FOV) for short breath hold. She also
presented research on a 3D MRI acquisition scheme that is
insensitive to motion and will enable free breathing MRI for
patients who are unable to hold their breath.
- Vivian Rodriguez, Ph.D., from
Washington University shared their
extensive experience with on-table adaptive therapy, illustrating
the significant anatomical changes that can take place within a
short period of time and highlighting case examples where the
treatment plan was reoptimized to escalate or de-escalate dose
based upon the proximity of nearby critical structures while the
patient was on the treatment table.
"With a single button click we can replan within a minute a new
treatment plan that reduces dose to organs at risk while giving a
greater dose to the target," said Dr. Rodriguez.
- Kathryn Mittauer, Ph.D., from
University of Wisconsin shared their
experience personalizing patient treatments through daily
dose-guided radiotherapy using online recalculation and evaluation
of the actual dose distribution.
"We're able to deliver higher doses to targets adjacent to organs
at risk due to improved confidence in treatment set up and delivery
that would not otherwise be clinically feasible," said Dr.
Mittauer.
To watch video recaps from some of the in-booth MRIdian user
presentations at AAPM, please visit
http://www.viewray.com/aapm_2017.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® and MRIdian Linac radiation
therapy systems. MRIdian integrates MRI technology, radiation
delivery and proprietary software to locate, target and track the
position and shape of soft-tissue tumors during radiation. ViewRay
believes this combination of enhanced visualization and accuracy
will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay,
Inc.
Forward Looking Statements:
This press release contains forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to the benefits of the
MRIdian System. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to raise the additional
funding needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize the MRIdian Linac, competition in the industry in
which ViewRay operates and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward- looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2016 and its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2017. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original
content:http://www.prnewswire.com/news-releases/early-clinical-experience-with-viewrays-mridian-linac-presented-at-leading-medical-physics-meeting-300499060.html
SOURCE ViewRay, Inc.